A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
Salima Hacein‐Bey‐Abina(Centre National de la Recherche Scientifique), Alain Fischer(Inserm), N. M. Wulffraat(Centre National de la Recherche Scientifique), Jean‐Luc Villeval(Inserm), Manfred Schmidt(Centre National de la Recherche Scientifique), Christof von Kalle(Luxembourg Institute of Health), Elisabeth McIntyre, Christopher C. Fraser, Marina Cavazzana(Université Rennes 2), Françoise Le Deist(Centre National de la Recherche Scientifique), Isabelle Radford
Cited by 1,847
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
|Science|2020|3.2k
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
|Science|2000|2.6k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k